Abstract：
:Alzheimer's disease (AD) is frequently associated with neuropsychiatric symptoms (NPS) such as agitation and aggression, especially in the moderate to severe stages of the illness. The limited efficacy and high-risk profiles of current pharmacotherapies for the management of agitation and aggression in AD have driven the search for safer pharmacological alternatives. Over the past few years, there has been a growing interest in the therapeutic potential of medications that target the endocannabinoid system (ECS). The behavioural effects of ECS medications, as well as their ability to modulate neuroinflammation and oxidative stress, make targeting this system potentially relevant in AD. This article summarizes the literature to date supporting this rationale and evaluates clinical studies investigating cannabinoids for agitation and aggression in AD. Letters, case studies, and controlled trials from four electronic databases were included. While findings from six studies showed significant benefits from synthetic cannabinoids—dronabinol or nabilone—on agitation and aggression, definitive conclusions were limited by small sample sizes, short trial duration, and lack of placebo control in some of these studies. Given the relevance and findings to date, methodologically rigorous prospective clinical trials are recommended to determine the safety and efficacy of cannabinoids for the treatment of agitation and aggression in dementia and AD.
journal_name
CNS Drugsjournal_title
CNS drugsauthors
Liu CS,Chau SA,Ruthirakuhan M,Lanctôt KL,Herrmann Ndoi
10.1007/s40263-015-0270-ysubject
Has Abstractpub_date
2015-08-01 00:00:00pages
615-23issue
8eissn
1172-7047issn
1179-1934pii
10.1007/s40263-015-0270-yjournal_volume
29pub_type
杂志文章,评审相关文献
CNS DRUGS文献大全abstract：BACKGROUND:The introduction of second-generation antipsychotics (SGAs) over the past 2 decades generated considerable optimism that better antipsychotic treatments for schizophrenia and bipolar disorder were possible. SGAs offer several tolerability benefits over first-generation antipsychotics (FGAs), particularly wit...
journal_title：CNS drugs
pub_type： 杂志文章,meta分析,评审
doi：10.2165/11634500-000000000-00000
更新日期：2012-09-01 00:00:00
abstract：:This review focuses on current information about luteal phase administration (i.e. typically for the last 2 weeks of the menstrual cycle) of pharmacological agents for the treatment of premenstrual dysphoric disorder (PMDD). Compared with continuous administration, a luteal phase administration regimen reduces the exp...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200418070-00004
更新日期：2004-01-01 00:00:00
abstract：OBJECTIVE:To assess the relationship between the sustained pain free (SPF) and adverse event (AE) rates associated with six oral serotonin 5-HT(1B/1D) receptor agonists (triptans) used for the treatment of acute migraine, employing data from a previous meta-analysis (that included almotriptan, eletriptan, naratriptan, ...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.2165/00023210-200721010-00006
更新日期：2007-01-01 00:00:00
abstract：:The circadian rhythm of pineal melatonin secretion, which is controlled by the suprachiasmatic nucleus (SCN), is reflective of mechanisms that are involved in the control of the sleep/wake cycle. Melatonin can influence sleep-promoting and sleep/wake rhythm-regulating actions through the specific activation of MT(1) (...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200721120-00004
更新日期：2007-01-01 00:00:00
abstract：:Attention-deficit/hyperactivity disorder, or ADHD, is the most frequently occurring neurobiological disorder in childhood and is defined by symptoms of inattention and/or hyperactivity and impulsivity that are excessive when compared with other individuals at the same developmental level. ADHD can be successfully trea...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-013-0130-6
更新日期：2014-02-01 00:00:00
abstract：BACKGROUND:Refractory status epilepticus (RSE) is an emergency with high mortality requiring neurointensive care. Treatment paradigms include first-generation antiepileptic drugs (AEDs) and anesthetics. Lacosamide (LCM) is a new AED, holding promise as a potent treatment option for RSE. High-level evidence regarding sa...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.1007/s40263-013-0049-y
更新日期：2013-04-01 00:00:00
abstract：:Pregabalin, the pharmacologically active S-enantiomer of 3-aminomethyl-5-methylhexanoic acid, possesses anticonvulsant activity. Pregabalin binds with high affinity and specificity to voltage-gated calcium channel alpha(2)-delta proteins. The putative mechanism of action of the drug is reduced excitatory neurotransmit...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200519030-00007
更新日期：2005-01-01 00:00:00
abstract：OBJECTIVE:This study examines the effects of parental lisdexamfetamine (LDX) treatment on parent-child interactions. METHODS:Participants were 30 parents (27% were male) and their children aged 5-12 years, both diagnosed with DSM-IV attention-deficit/hyperactivity disorder (ADHD). Optimal LDX dose (30, 50, or 70 mg/da...
journal_title：CNS drugs
pub_type： 杂志文章,随机对照试验
doi：10.1007/s40263-014-0165-3
更新日期：2014-07-01 00:00:00
abstract：:Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial-onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial-onset seizu...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/11208340-000000000-00000
更新日期：2011-10-01 00:00:00
abstract：:There have been significant developments in the understanding of depression in children and adolescents in the past few years, including an increased recognition that significant depressive illness occurs in this patient group. Pharmacological and psychotherapeutic treatments are used to manage depression in children ...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200620010-00001
更新日期：2006-01-01 00:00:00
abstract：:Neuropathic pain is a persistent pain condition that develops secondary to nerve injury. The two most common types of peripheral neuropathic pain are post-herpetic neuralgia (PHN) and painful diabetic neuropathy (PDN). Amitriptyline, nortriptyline, desipramine and imipramine are TCAs that have been shown to be effecti...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200822050-00005
更新日期：2008-01-01 00:00:00
abstract：:Existing drug delivery methods have not led to a significant increase in survival for patients with malignant primary brain tumors. While the combination of conventional therapies consisting of surgery, radiotherapy, and chemotherapy has improved survival for some types of brain tumors (e.g., WNT medulloblastoma), oth...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-020-00766-w
更新日期：2020-11-01 00:00:00
abstract：:Parkinson's disease is a disabling hypokinetic neurological movement disorder in which the aetiology is unknown in the majority of cases. Current pharmacological treatments, though effective at restoring movement, are only symptomatic and do nothing to slow disease progression. Electrophysiological, epidemiological an...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-016-0393-9
更新日期：2016-12-01 00:00:00
abstract：:Once considered rare and resistant to treatment, obsessive-compulsive disorder (OCD) has now emerged as a common, yet often unrecognized, psychiatric condition. Treatment with selective serotonin reuptake inhibitors (SSRIs) is effective in 40-60% of patients with OCD. Management of the remaining 40-60% of patients wit...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/11587860-000000000-00000
更新日期：2011-07-01 00:00:00
abstract：:The eating disorders anorexia nervosa and bulimia nervosa present with comorbidity in a number of important areas, including depression, bipolar disorder, anxiety disorders (obsessive-compulsive disorder, panic disorder, social anxiety disorder and other phobias, and post-traumatic stress disorder) and substance abuse...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200620080-00004
更新日期：2006-01-01 00:00:00
abstract：BACKGROUND:There are few data about the cost effectiveness of prophylactic medications for migraine. Clinical trials have shown several preventive agents to be useful in reducing the frequency of migraine attack while having tolerable side effects. OBJECTIVE:To compare the cost effectiveness of adding preventive treat...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.2165/11531180-000000000-00000
更新日期：2010-08-01 00:00:00
abstract：:The link between diabetes mellitus and Alzheimer's disease (AD) has been known for the last few decades. Since insulin and insulin receptors are known to be present in the brain, the downstream signalling as well as the effect of hyperinsulinemia have been extensively studied in both AD and Parkinson's disease. Glucag...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-015-0301-8
更新日期：2015-12-01 00:00:00
abstract：BACKGROUND:When otherwise unexplained, syncope in patients with Alzheimer's disease may be attributed to bradycardia caused by cholinesterase inhibitors. We studied prospectively the clinical events and cardiovascular changes occurring during treatment with donepezil in patients with Alzheimer's disease. METHODS:Conse...
journal_title：CNS drugs
pub_type： 临床试验,杂志文章
doi：10.2165/00023210-200620050-00005
更新日期：2006-01-01 00:00:00
abstract：UNLABELLED:Tianeptine is an antidepressant agent with a novel neurochemical profile. It increases serotonin (5-hydroxytryptamine; 5-HT) uptake in the brain (in contrast with most antidepressant agents) and reduces stress-induced atrophy of neuronal dendrites. Like the selective serotonin reuptake inhibitors (SSRIs) and...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200115030-00006
更新日期：2001-01-01 00:00:00
abstract：BACKGROUND:Responses to atomoxetine vary for individual patients with attention-deficit/hyperactivity disorder (ADHD). However, we do not know whether any factors can be used to reliably predict how individuals with ADHD will respond to treatment. OBJECTIVE:Our objective was to evaluate background variables that facil...
journal_title：CNS drugs
pub_type： 临床试验,杂志文章
doi：10.1007/s40263-016-0323-x
更新日期：2016-04-01 00:00:00
abstract：:Risperidone (Risperdal), a psychotropic atypical antipsychotic agent, is thought to act via dopamine D(2) and serotonin 5-HT(2A) receptor antagonism. The clinical efficacy of oral risperidone in the treatment of bipolar mania and schizophrenia in adult patients is well established. In the US, risperidone is also appro...
journal_title：CNS drugs
pub_type： 评论,杂志文章
doi：10.2165/00023210-200822030-00006
更新日期：2008-01-01 00:00:00
abstract：:The coronavirus 2019 (COVID-19) pandemic is expected to linger. Decisions regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have to consider the potential relevance to the pandemic. Understanding the mechanism of action and the possible idiosyncratic effects of each therapeutic a...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-020-00756-y
更新日期：2020-09-01 00:00:00
abstract：:Insomnia, an inability to initiate or maintain sleep, affects approximately one-third of the American population. Conventional benzodiazepines, such as triazolam and midazolam, were the treatment of choice for short-term insomnia for many years but are associated with adverse effects such as rebound insomnia, withdraw...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200317070-00004
更新日期：2003-01-01 00:00:00
abstract：:Multiple stimulant and non-stimulant medications are approved for the treatment of attention-deficit/hyperactivity disorder (ADHD), one of the most prevalent childhood neurodevelopmental disorders. Choosing among the available agents and determining the most effective ADHD medication for a given child can be a time-co...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-020-00702-y
更新日期：2020-04-01 00:00:00
abstract：:Anticonvulsant hypersensitivity syndrome (AHS) is a rare, but potentially fatal, adverse reaction that occurs in patients, including children, who are treated with anticonvulsants. During metabolism of the anticonvulsant, toxic arene-oxide compounds are produced. AHS is associated with both cutaneous and systemic symp...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200216030-00006
更新日期：2002-01-01 00:00:00
abstract：:For nearly 50 years, antidepressant drugs have been the first-line treatment for various forms of depression. Despite their widespread use, these medications have significant shortcomings, in particular problems of patient compliance due to adverse effects. The introduction of new formulations of existing antidepressa...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200418080-00003
更新日期：2004-01-01 00:00:00
abstract：:Given the high heritability of the disorder, attention-deficit hyperactivity disorder (ADHD) is common among parents of children with ADHD. Parental ADHD is associated with maladaptive parenting, negative parent-child interaction patterns and a diminished response to behavioural parent training. We describe our previo...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.2165/11633910-000000000-00000
更新日期：2012-09-01 00:00:00
abstract：:Statins, or 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, such as lovastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, rosuvastatin and pitavastatin, are cholesterol-lowering drugs used in clinical practice to prevent coronary heart disease. These drugs are generally well tolerated and have ...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-013-0135-1
更新日期：2014-03-01 00:00:00
abstract：:Restless legs syndrome (RLS) is a common, frequently chronic, sensorimotor neurological disorder characterized by nocturnal leg dysesthesias and an irresistible urge to move the legs, usually resulting in sleep disturbance. Dopaminergic agonists, alpha-2-delta calcium-channel ligands, and opioids have all demonstrated...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-015-0250-2
更新日期：2015-05-01 00:00:00
abstract：:Duloxetine (Cymbalta(R)) is a potent serotonin and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) in the CNS. It is indicated for the treatment of generalized anxiety disorder (GAD) as well as other indications. In patients with GAD of at least moderate severity, oral duloxetine 60-120 mg once daily was effe...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200923060-00006
更新日期：2009-01-01 00:00:00
